We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 58,159 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/12/2016 13:04 | F3 i guess with her involvement with soon to be listed Skin bio then J&J are sure to be involved. | john henry | |
10/12/2016 08:19 | I do wonder where J&J fit into all this! Are they still working with Dr O'Neil developing understanding of the microbiome- does this now include OPTI? | f3rdinand | |
09/12/2016 21:33 | I wonder if Opti will partner with her other company, namely Curapel - it has three skin products in late stage development. hxxp://www.financewa | mazzstar | |
09/12/2016 21:00 | Nice one mazzstar, very interesting and a very enthusiastic Cath O'Neil, just a matter of being patient 2017 will be our year. GLA. | warren1982 | |
09/12/2016 19:56 | Interesting video on how Cath O'Neill formed Skinbiotix (starts around the 2 min mark): | mazzstar | |
09/12/2016 17:50 | The "must be news leaked" gang when we are 2p up are nearky as bad | judijudi | |
09/12/2016 17:45 | Elrico, I'm free on Thurs afternoon. I might even buy him a colouring book... | 1bokke | |
09/12/2016 16:47 | :) Fair play Elrico | judijudi | |
09/12/2016 16:35 | JJ - The fool can barely string a sentence together. Anyone can pluck a figure out of the air, in his case, it was clearly guesswork based on NO TA or anything you could give him CREDIT for. He is a wind up merchant. He seeks a reaction because lonely souls like him need to feed off people. Last I checked before I filtered it, he NEVER strung two lines together, not a single piece of original research or opinion backed with any thought process. He is invested in CPX, another jam tomorrow company that has had its truckStart module selling to truck OEMs and aftermarket chains for less than $500, a significant reduction from the $1,000 price that was previously envisaged. Even investors their filter him because of his antics. I wonder what price he has put on this rent and ramper company? If he would just let us know which institution he sectioned in, perhaps we could arrange visits to keep him company. Any takers? I'll put my name down on the rota. | elrico | |
09/12/2016 16:14 | He's actually been correct here more than anybody I think he's wrong now though | judijudi | |
09/12/2016 16:11 | monkeywench1 is definitely one of the dimmest on ADVFN, especially as being a premium member, he actually pays to write tripe, the only slight compensation is that he can tick down post's | neftanikoff | |
09/12/2016 15:48 | down she goes...50p soon. | monkeywench1 | |
09/12/2016 15:00 | shame we could not muster a couple of up days on the trot. | neftanikoff | |
09/12/2016 12:02 | I know OPTI have fingers in more than one pie and it'll only take one of them to come good to move that share price up,but as for the sugar substitute there is a lot out there and it'll have to be a gud un to pay off. hxxp://www.shareprop | scotty1 | |
09/12/2016 11:30 | pglancy - You are right to be cautious and question such posts. I have no issue with your question, just the way it is worded in an accusing manner. In truth, short of SOH posting to confirm it's authenticity, I have no way of proving it is genuine, so you will have to decide for yourself. I know others that have had personal contact with SOH, so they are aware he is very approachable as long as boundaries are respected. I would soon be found out if I lied and thus what little credibility I may have will be lost and all future comments by me would be an exercise in futility. In short, no matter how good your posts, research have been in the past, get caught lying and you are done for. People don't forget liars and deceivers in this arena. | elrico | |
09/12/2016 11:24 | Mouse: thank you for that video link to Rob Knight keynote speech. Very entertaining in parts, complex in others (was it ever thus ;0). Interesting point in the Q & A that you also picked up, which I repeat here: Probiotic commercial products: "But a lot of that is happening in Europe and Japan where the regulatory framework is a lot more favourable than in the U.S. In the U.S. where you prove your probiotic works, it gets re-regulated from a supplement to a drug and you have to do $2 billion of clinical trials before you can market it again, it’s kind of like a sports supplement doesn’t work by the fact that it is legal, probiotics that have been seen to work in clinical trials are extremely rare in the U.S. for that reason." Best wishes - Mike | spike_1 | |
08/12/2016 23:55 | elrico, are you honestly saying you got a reply from a ceo within 25 minutes at this late hour? | pglancy | |
08/12/2016 23:44 | Mouse - Amazingly I got a very prompt reply from SOH; "Unusually the US market is less stringent than the European market. The issue in all territories is not about use of probiotics as this is a $40bn market, more about what you can claim on packaging to consumers. That's the reason I chose cholesterol first as it's an established biomarker of cardiovascular risk." Hope this helps. Steve This confirms my links above, particularly the 1st, science daily. | elrico | |
08/12/2016 23:22 | Mouse - First I must be clear, I do not have SOH's ear - He phoned me just the once, though it was quite lengthy, I do not have my feet under his table. :-) That said, I have asked the question - will I get a response? We shall see. You ask a very good question and one I had a look at about a year ago. The link demonstrates the need for clarity for regulatory approvals via FDA for "probiotics" and this seems to be based on some concerns about claims by manufacturers rather than the hurdles to gain approval. EU uses GRAS, US uses CAM - If I understand correctly. | elrico | |
08/12/2016 21:11 | Calm down Ferdi! - surely it was a buy as the price was rising all day? | whl2 | |
08/12/2016 20:57 | Well worth watching. At least for the science geeks. Keynote rob knight. Shaping Our Dynamic Microbiomes For Lifelong Health ... One interesting point that might be worth clarifying with SOH (Elrico or someuwin) is that any probiotic supplement effect that is proven to clinically work(e.g. Lp-ldl)must be then reclassified as a drug in the US and go through the expensive pharma regs before it can be sold. This is not the case in Europe. But that sounds like it might impact on the US market. | mouse20 | |
08/12/2016 20:37 | Mazz - Ref TW & AR (P&G) - you could well be correct. Whomever the source is I don't really care as long as the source is correct and has not jumped the gun. TW is a marmite character, but one thing I will say in his favour - he doesn't suffer fools, so I am sure he would have fact checked such a claim. He has quoted P&G 2 or 3 times to my knowledge, months apart. Fozdad - apologies, I may have been a tad harsh or did I just forget to add ;-) But yes, someuwin is correct in that we do have six commercial agreement across at platforms...two of which have significantly been derisked. | elrico | |
08/12/2016 18:43 | He most definitely is the source! Although he clearly knows sweet FA about OPTI really as all his predictions are way out! who remembers the massive deal that was due to be completed before Easter..He's only on the board as he organised the reverse take over! | f3rdinand | |
08/12/2016 18:16 | May I also mention that TW bought warrants in both Opti and Concepta at 8p on the advice of Adam Reynolds. In my opinion, he is TW's source. | mazzstar |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions